MDMA Therapy in Veterans With PTSD

Summary

A Phase 2, single-center, fixed-dose, open-label study will explore the efficacy, safety, and tolerability of a 120 mg dose of oral MDMA followed by a supplemental dose of 60 mg MDMA in conjunction with therapy in individual versus group settings for adult veterans diagnosed with PTSD.

Timeline

Start

2026-06-30

Primary completion

2027-04-01

Completion

2027-08

Drugs

Indications